Intraoperative blood loss as an independent prognostic factor for curative resection after neoadjuvant chemotherapy for gastric cancer: a single-center retrospective cohort study.
Aged
Blood Loss, Surgical
/ statistics & numerical data
Body Mass Index
Female
Hepatectomy
/ adverse effects
Humans
Intraoperative Period
Male
Middle Aged
Neoadjuvant Therapy
Postoperative Complications
/ etiology
Prognosis
Retrospective Studies
Stomach Neoplasms
/ drug therapy
Surgical Wound Infection
/ etiology
Survival Rate
Blood loss
Gastric cancer
Neoadjuvant chemotherapy
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
18
04
2020
accepted:
14
07
2020
pubmed:
26
8
2020
medline:
6
7
2021
entrez:
26
8
2020
Statut:
ppublish
Résumé
Surgery-induced factors such as postoperative infectious complications (PICs) and intraoperative blood loss (IBL) have a negative impact on the survival of patients undergoing surgery for gastric cancer. A recent study showed that neoadjuvant chemotherapy (NAC) could reduce the negative impact of PICs; hence, we conducted the present study to investigate if NAC can also reduce the negative prognostic impact of IBL. We reviewed 115 gastric cancer patients treated with NAC and radical gastrectomy. The cut-off for IBL predicting the long-term survival was assessed by a receiver operating characteristic curve. The Cox proportional hazard model was used to evaluate the association between patient characteristics including IBL, overall survival, and disease-free survival. The cut-off for IBL was set at 990 ml. Twenty-six patients had excessive IBL exceeding 990 ml (22.6%) and PICs developed in 33 patients (28.7%). The body mass index, IBL, ypT, and ypN were significant independent prognostic predictors, but PICs were not. NAC did not decrease the risk induced by excessive IBL. The prophylactic effect of NAC on surgery-induced risk was inconsistent.
Identifiants
pubmed: 32839832
doi: 10.1007/s00595-020-02114-3
pii: 10.1007/s00595-020-02114-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-302Références
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64. https://doi.org/10.1016/S0140-6736(16)30354-3 (Epub 2016 May 5).
doi: 10.1016/S0140-6736(16)30354-3
pubmed: 27156933
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
doi: 10.1056/NEJMoa055531
Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015–22. https://doi.org/10.1002/bjs.6665 .
doi: 10.1002/bjs.6665
pubmed: 19644974
Tsuburaya A, Nagata N, Cho H, Hirabayashi N, Kobayashi M, Kojima H, et al. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol. 2013;71:1309–14. https://doi.org/10.1007/s00280-013-2130-0 (Epub 2013 Mar 5).
doi: 10.1007/s00280-013-2130-0
pubmed: 23463482
Kosaka T, Akiyama H, Makino H, Takagawa R, Kimura J, Ono H, et al. Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol. 2014;73:281–5. https://doi.org/10.1007/s00280-013-2350-3 (Epub 2013 Nov 20).
doi: 10.1007/s00280-013-2350-3
pubmed: 24253176
Oki E, Emi Y, Kusumoto T, Sakaguchi Y, Yamamoto M, Sadanaga N, et al. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer. Ann Surg Oncol. 2014;21:2340–6. https://doi.org/10.1245/s10434-014-3594-9 (Epub 2014 Mar 7).
doi: 10.1245/s10434-014-3594-9
pubmed: 24604583
Tsuburaya A1, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60. https://doi.org/10.1002/bjs.9484 (Epub 2014 Mar 25).
doi: 10.1002/bjs.9484
pubmed: 24668391
Eto K, Hiki N, Kumagai K, Shoji Y, Tsuda Y, Kano Y, et al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer. 2018;21:703–9. https://doi.org/10.1007/s10120-017-0781-y (Epub 2017 Nov 29).
doi: 10.1007/s10120-017-0781-y
pubmed: 29188456
Kamei T, Kitayama J, Yamashita H, Nagawa H. Intraoperative blood loss is a critical risk factor for peritoneal recurrence after curative resection of advanced gastric cancer. World J Surg. 2009;33:1240–6. https://doi.org/10.1007/s00268-009-9979-4 .
doi: 10.1007/s00268-009-9979-4
pubmed: 19308640
Liang YX, Guo HH, Deng JY, Wang BG, Ding XW, Wang XN, et al. Impact of intraoperative blood loss on survival after curative resection for gastric cancer. World J Gastroenterol. 2013;19:5542–50. https://doi.org/10.3748/wjg.v19.i33.5542 .
doi: 10.3748/wjg.v19.i33.5542
pubmed: 24023499
pmcid: 3761109
Mizuno A, Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, et al. Adverse Effects of Intraoperative Blood Loss on Long-Term Outcomes after Curative Gastrectomy of Patients with Stage II/III Gastric Cancer. Dig Surg. 2016;33:121–8. https://doi.org/10.1159/000443219 (Epub 2016 Jan 9).
doi: 10.1159/000443219
pubmed: 26745751
Ito Y, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, et al. Intraoperative Blood Loss is Associated with Shortened Postoperative Survival of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-institutional Dataset. World J Surg. 2018. https://doi.org/10.1007/s00268-018-4834-0 (Epub ahead of print).
doi: 10.1007/s00268-018-4834-0
pubmed: 30051240
pmcid: 6329739
Hyung WJ, Noh SH, Shin DW, Huh J, Huh BJ, Choi SH, et al. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol. 2002;9:5–12.
doi: 10.1245/aso.2002.9.1.5
Dhar DK, Kubota H, Tachibana M, Kotoh T, Tabara H, Watanabe R, et al. Long-term survival of transmural advanced gastric carcinoma following curative resection: multivariate analysis of prognostic factors. World J Surg. 2000;24:588–93 (discussion 593–4).
doi: 10.1007/s002689910099
Arigami T, Uenosono Y, Yanagita S, Okubo K, Kijima T, Matsushita D, et al. Clinical significance of circulating tumor cells in blood from patients with gastric cancer. Ann Gastroenterol Surg. 2017;2017(1):60–8. https://doi.org/10.1002/ags3.12005.eCollection .
doi: 10.1002/ags3.12005.eCollection
Zhou J, Ma X, Bi F, Liu M. Clinical significance of circulating tumor cells in gastric cancer patients. Oncotarget. 2017;8:25713–20. https://doi.org/10.18632/oncotarget.14879 .
doi: 10.18632/oncotarget.14879
pubmed: 28147337
pmcid: 5421964
Toyoshima K, Hayashi A, Kashiwagi M, Hayashi N, Iwatsuki M, Ishimoto T, et al. Analysis of circulating tumor cells derived from advanced gastric cancer. Int J Cancer. 2015;137:991–8. https://doi.org/10.1002/ijc.29455 (Epub 2015 Feb 13).
doi: 10.1002/ijc.29455
pubmed: 25622566
Hayashi M, Yoshikawa T, Yura M, Otsuki S, Yamagata Y, Morita S, et al. Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy? Gastric Cancer. 2019. https://doi.org/10.1007/s10120-019-00957-5 .
doi: 10.1007/s10120-019-00957-5
pubmed: 31055693
Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12. https://doi.org/10.1007/s10120-011-0041-5 .
doi: 10.1007/s10120-011-0041-5
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46(6):668–85. https://doi.org/10.1007/s00595-015-1236-x (Epub 2015 Aug 20).
doi: 10.1007/s00595-015-1236-x
pubmed: 26289837
pmcid: 26289837
Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, et al. Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas. Pancreas. 2011;40(1):3–9. https://doi.org/10.1097/MPA.0b013e3181f7147a .
doi: 10.1097/MPA.0b013e3181f7147a
pubmed: 20881897
Katz SC, Shia J, Liau KH, Gonen M, Ruo L, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 2009;249:617–23. https://doi.org/10.1097/SLA.0b013e31819ed22f .
doi: 10.1097/SLA.0b013e31819ed22f
pubmed: 19300227
Mörner MEM, Gunnarsson U, Jestin P, Svanfeldt M. The importance of blood loss during colon cancer surgery for long-term survival: an epidemiological study based on a population based register. Ann Surg. 2012;255:1126–8. https://doi.org/10.1097/SLA.0b013e3182512df0 .
doi: 10.1097/SLA.0b013e3182512df0
pubmed: 22498893
Bruns CJ, Schäfer H, Wolfgarten B, Engert A. Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract. Langenbecks Arch Chir Suppl Kongressbd. 1996;113:146–9.
pubmed: 9101816
Normando SRC, Delgado PO, Rodrigues AKSB, David Filho WJ, Fonseca FLA, Cruz FJSM, et al. (2018) Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy. BMC Clin Pathol. 2018;18:12. https://doi.org/10.1186/s12907-018-0079-y (eCollection 2018).
doi: 10.1186/s12907-018-0079-y
pubmed: 30498396
pmcid: 6258437
Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575–83. https://doi.org/10.1245/s10434-012-2720-9 (Epub 2012 Oct 18).
doi: 10.1245/s10434-012-2720-9
pubmed: 23076557
Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, et al. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014;21:891–8. https://doi.org/10.1245/s10434-013-3384-9 (Epub 2013 Nov 20).
doi: 10.1245/s10434-013-3384-9
pubmed: 24254205
Sierzega M, Kolodziejczyk P, Kulig J. Impact of anastomotic leakage on long-term survival after total gastrectomy for carcinoma of the stomach. Br J Surg. 2010;97:1035–42. https://doi.org/10.1002/bjs.7038 .
doi: 10.1002/bjs.7038
pubmed: 20632269